We're empowering microbiology labs to prevent and treat infections with nucleic acid sequencing.
Vancouver, Canada
Joined April 2020
- Tweets232
- Following184
- Followers203
- Likes73
Pinned Tweet
BugSeq leads clinical bioinformatics in consortium (@Ginkgo, @JumpcodeG , @planetinnovate , @TGenResearch , and more) developing end-to-end metagenomic solution for @EU_HaDEA.
See our announcement here: bugseq.com/news/2025/02/20/B…
Today, we're thrilled to announce RANGER: RApid Next Generation Sequencing for Effective Medical Response, a consortium project supported by the @EU_HaDEA.
hubs.la/Q037vZ770
From targeted ITS sequencing direct from sample to WGS for outbreak strain typing: see how @nanopore and BugSeq enable rapid fungal pathogen characterisation.
Register (offered in two time zones):
nanoporetech.com/about/event…
Join researchers from Jessa Hospital and Tampa General Hospital who will share their clinical research workflow considerations, validation data, and implementation insights using nanopore sequencing and BugSeq analysis for fungal pathogen ID.
bit.ly/4hgzpeS
RUO
As metagenomic next-generation sequencing technology is increasingly used in clinical laboratories, BugSeq announces two new efforts to push mNGS technology towards regulated diagnostic use.
Read the full details here: bugseq.com/news/2026/10/01/B…
Another great example from the team at @JessaZiekenhuis using BugSeq to analyze @nanopore sequencing data in routine clinical microbiology!
doi.org/10.3389/fmicb.2026.1…
.@JessaZiekenhuis, evaluating BugSeq for characterization of #AMR and outbreak analysis in Pseudomonas aeruginosa, found “the overall categorical agreement (% [95% CI]) between AMR genotype and phenotype was 94.76% [92.46%–96.52%]”.
Read more: doi.org/10.1128/jcm.00572-26
BugSeq retweeted
New genomic tools are helping strengthen Canada's response to emerging pathogens and antimicrobial resistance.
@techcouver
@bugseq
Read more: techcouver.com/2026/08/04/wi…
#Genomics #PublicHealth #AMR #AntimicrobialResistance #InnovationBC
.@JessaZiekenhuis, evaluating BugSeq for characterization of #AMR and outbreak analysis in Pseudomonas aeruginosa, found “the overall categorical agreement (% [95% CI]) between AMR genotype and phenotype was 94.76% [92.46%–96.52%]”.
Read more: doi.org/10.1128/jcm.00572-26
Speed up your lab's #Cyclospora surveillance with the BugSeq platform. Contact us for early access to our new Cyclospora cayetanensis MLST module, which delivers typing from WGS and metagenomics!
We’re proud to team up with @GenomeBC on a new initiative to advance #Genomics in the fight against antimicrobial resistance!
From scaling our #BugAMR platform to refining tools for rapid pathogen detection, we’re focused on one goal: faster, life-saving insights for healthcare.
2 new research projects with BC-based biotech company @bugseq to advance genomic tools that improve antimicrobial resistance prediction and respiratory pathogen detection.
Faster answers. Better treatment decisions. Stronger public health systems.
genomebc.ca/?p=36516
Fantastic demonstration by the @AdventHealth team of the power of BugSeq in clinical practice: “Rapid and Routinely 24-Hour Antimicrobial Resistance Report for Mycobacterium abscessus Group by Whole-Genome Sequencing: A Tool for Appropriate Antimicrobial Therapy” 👇
Join BugSeq at ASM Microbe to see innovation in action! See the full BugSeq schedule, including demonstrations from our users: bugseq.com/resources/confere…
Check out recent updates to the BugSeq platform in our latest blog post: Advancing Viral Surveillance, Sequencing Flexibility, AMR Prediction, and EPI2ME Integration
docs.bugseq.com/blog/2026/05…
At #PASCV2026 ? Drop by the BugSeq booth (02T) to see how the most innovative labs are leveraging NGS to track viral outbreaks, antiviral resistance and more (and don’t forget to grab a notebook or bag)!
⏰ 16:15-17:15 CEST
📍 #Bioinformatics Pipeline Corner, Arena 4
🗣️ Sam Chorlton, BugSeq CEO
See how we leverage interpretable AI to aid clinical translation and deliver industry-leading accuracy in:
🦠 Pathogen ID
💊 AMR prediction
📈 Outbreak analysis
#ESCMIDGlobal2026
At #ESCMIDGlobal2026? Come visit booth H11 to learn more about how BugSeq can power your infectious disease bioinformatic workflows! From pathogen identification to AMR and outbreak analysis, BugSeq has a suite of analysis tools to power your NGS workflows.
Did you know you can now submit data to BugSeq directly through the @nanopore EPI2ME platform? Submitting ONT sequence data to BugSeq is now easier than ever! Check out the blog post for more details on the integration between ONT and BugSeq: epi2me.nanoporetech.com/epi2…
Interested in learning more about leveraging BugSeq’s suite of infectious disease bioinformatic workflows with your @nanopore sequence data? Check out the ONT Booth at #ESCMIDGlobal2026 for a live demonstration and more details (full schedule below): nanoporetech.com/about/event…
The power of a curated database: BugSeq was most accurate for species identification in an independent evaluation of cloud-based platforms for microbial whole genome sequencing analysis. Read more: doi.org/10.1017/ash.2026.103…
Miss the recent publication (doi.org/10.1128/jcm.01348-25) from @HopkinsMedicine leveraging BugSeq for infection control of C. auris? Stop by our booth at #SHEASpring2026 to learn how BugSeq powers genomic infection control programs.
BugSeq is delighted to partner with @UBC to improve detection, surveillance and early identification of emerging respiratory pathogens across Canada.
BC researchers are receiving $8M in federal funding to fast-track genomic solutions 🧬
8 teams will advance real-world projects, from pathogen detection to improved care for cancer, Type 1 diabetes and endometriosis.
Part of a $20M @GenomeCanada GAPP investment.
@BCCancer @SFU @UB @AbCelleraBio @ubcmsl
Find out more: genomebc.ca/blog/bc-research…
Through this effort, the team will validate BugSeq’s bioinformatic platform to improve patient outcomes and strengthen Canadian biosecurity and pandemic preparedness.
This program is supported by @GenomeCanada and @GenomeBC through the Genomic Applications Partnership Program. Learn more about the program in the announcement.